Search Results - "Bertino, Erin"

Romidepsin: a novel histone deacetylase inhibitor for cancer by Bertino, Erin M, Otterson, Gregory A

“…Romidepsin is a novel histone deacetylase (HDAC) inhibitor, with a recent approval for treatment of cutaneous T-cell lymphoma (CTCL). HDAC inhibitors represent…”
Get more information

Second cancer incidence in CLL patients receiving BTK inhibitors by Bond, David A., Huang, Ying, Fisher, James L., Ruppert, Amy S., Owen, Dwight H., Bertino, Erin M., Rogers, Kerry A., Bhat, Seema A., Grever, Michael R., Jaglowski, Samantha M., Maddocks, Kami J., Byrd, John C., Woyach, Jennifer A.

“…Chronic lymphocytic leukemia (CLL) is associated with perturbed immune function and increased risk for second primary malignancies (SPM). Ibrutinib and…”
Get full text

Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers by Li, Mingjia, Spakowicz, Daniel, Burkart, Jarred, Patel, Sandip, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Carbone, David P., Verschraegen, Claire F., Presley, Carolyn J., Otterson, Gregory A., Kendra, Kari, Owen, Dwight H.

“…Background The neutrophil to lymphocyte ratio (NLR) is known to be prognostic for patients with advanced cancers treated with immune checkpoint inhibitors…”
Get full text

Consensus guidelines for the management and treatment of neuroendocrine tumors by Kunz, Pamela L, Reidy-Lagunes, Diane, Anthony, Lowell B, Bertino, Erin M, Brendtro, Kari, Chan, Jennifer A, Chen, Herbert, Jensen, Robert T, Kim, Michelle Kang, Klimstra, David S, Kulke, Matthew H, Liu, Eric H, Metz, David C, Phan, Alexandria T, Sippel, Rebecca S, Strosberg, Jonathan R, Yao, James C

“…Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant…”
Get full text

Advances in epigenetic therapeutics with focus on solid tumors by Jin, Ning, George, Tiffany L, Otterson, Gregory A, Verschraegen, Claire, Wen, Haitao, Carbone, David, Herman, James, Bertino, Erin M, He, Kai

“…Epigenetic ("above genetics") modifications can alter the gene expression without altering the DNA sequence. Aberrant epigenetic regulations in cancer include…”
Get full text

Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non–Small-cell Lung Cancer by Owen, Dwight H., Wei, Lai, Bertino, Erin M., Edd, Thomas, Villalona-Calero, Miguel A., He, Kai, Shields, Peter G., Carbone, David P., Otterson, Gregory A.

“…The risk factors for immune-related adverse events (irAEs) remain undefined. Recently, a correlation between irAEs and clinical benefit was suggested. We…”
Get full text

Podcast on the Management of Adverse Events Associated with Lorlatinib by Bauer, Todd M., Bertino, Erin M.

“…ApX97eePwXKhLV3yjS-RLA Video: Lorlatinib podcast video…”
Get full text

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies by Shukuya, Takehito, Mori, Keita, Amann, Joseph M, Bertino, Erin M, Otterson, Gregory A, Shields, Peter G, Morita, Satoshi, Carbone, David P

“…Alternative predictive end points for overall survival (OS), such as tumor response and progression-free survival (PFS), are useful in the early detection of…”
Get more information

Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival by Haddad, Tyler C., Zhao, Songzhu, Li, Mingjia, Patel, Sandip H., Johns, Andrew, Grogan, Madison, Lopez, Gabriella, Miah, Abdul, Wei, Lai, Tinoco, Gabriel, Riesenberg, Brian, Li, Zihai, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Otterson, Gregory, Presley, Carolyn J., Owen, Dwight H.

“…Introduction Immune checkpoint inhibitors (ICI) are associated with unique immune-related adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an…”
Get full text

Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival by Miah, Abdul, Tinoco, Gabriel, Zhao, Songzhu, Wei, Lai, Johns, Andrew, Patel, Sandip, Li, Mingjia, Grogan, Madison, Lopez, Gabrielle, Husain, Marium, Hoyd, Rebecca, Mumtaz, Khalid, Meara, Alexa, Bertino, Erin M., Kendra, Kari, Spakowicz, Daniel, Otterson, Gregory A., Presley, Carolyn J., Owen, Dwight H.

“…Purpose Immune checkpoint inhibitors (ICIs) are associated with a unique set of immune-related adverse events (irAEs). Few studies have evaluated the risk…”
Get full text

ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges by Chow, Laura Q M, Barlesi, Fabrice, Bertino, Erin M, van den Bent, Martin J, Wakelee, Heather A, Wen, Patrick Y, Chiu, Chao-Hua, Orlov, Sergey, Chiari, Rita, Majem, Margarita, McKeage, Mark, Yu, Chong-Jen, Garrido, Pilar, Hurtado, Felipe K, Arratia, Pilar Cazorla, Song, Yuanbo, Branle, Fabrice, Shi, Michael, Kim, Dong-Wan

“…Central nervous system metastases are a prominent cause of morbidity and mortality in patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC). The…”
Get full text

Pulmonary Neuroendocrine/Carcinoid Tumors: A Review Article by BERTINO, Erin M, CONFER, Patricia D, COLONNA, Jorge E, ROSS, Patrick, OTTERSON, Gregory A

“…Neuroendocrine tumors are a unique malignant neoplasm that can arise from the respiratory tree. Although well-differentiated bronchial neuroendocrine tumors…”
Get full text

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors by Qin, Angel, Zhao, Songzhu, Miah, Abdul, Wei, Lai, Patel, Sandipkumar, Johns, Andrew, Grogan, Madison, Bertino, Erin M, He, Kai, Shields, Peter G, Kalemkerian, Gregory P, Gadgeel, Shirish M, Ramnath, Nithya, Schneider, Bryan J, Hassan, Khaled A, Szerlip, Nicholas, Chopra, Zoey, Journey, Sara, Waninger, Jessica, Spakowicz, Daniel, Carbone, David P, Presley, Carolyn J, Otterson, Gregory A, Green, Michael D, Owen, Dwight H

“…Bone metastases and skeletal-related events (SREs) are a frequent cause of morbidity in patients with metastatic non-small cell lung cancer (mNSCLC). Data are…”
Get more information

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR -mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903) by Bertino, Erin M, Gentzler, Ryan D, Clifford, Sarah, Kolesar, Jill, Muzikansky, Alona, Haura, Eric B, Piotrowska, Zofia, Camidge, D Ross, Stinchcombe, Thomas E, Hann, Christine, Malhotra, Jyoti, Villaruz, Liza C, Paweletz, Cloud P, Lau, Christie L, Sholl, Lynette, Takebe, Naoko, Moscow, Jeffrey A, Shapiro, Geoffrey I, Jänne, Pasi A, Oxnard, Geoffrey R

“…Osimertinib is an effective therapy in -mutant non-small cell lung cancer (NSCLC), but resistance invariably develops. Navitoclax is an oral inhibitor of…”
Get full text

A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer by Bertino, Erin M, McMichael, Elizabeth L, Mo, Xiaokui, Trikha, Prashant, Davis, Melanie, Paul, Bonnie, Grever, Michael, Carson, William E, Otterson, Gregory A

“…mAbs can induce antibody-dependent cellular cytotoxicity (ADCC) via the innate immune system's ability to recognize mAb-coated cancer cells and activate immune…”
Get full text

Feasibility of an embedded palliative care clinic model for patients with an advanced thoracic malignancy by Bertino, Erin M., Grogan, Madison M., Benedict, Jason A., Agne, Julia L., Janse, Sarah, Eastep, Christine, Sullivan, Diana, Gast, Kelly C., Naughton, Michelle J., Presley, Carolyn J.

“…Purpose Early palliative care (PC) with standard oncology care has demonstrated improved patient outcomes, but multiple care delivery models are utilized. This…”
Get full text

Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With a New Thoracic Malignancy by Gast, Kelly C, Benedict, Jason A, Grogan, Madison, Janse, Sarah, Saphire, Maureen, Kumar, Pooja, Bertino, Erin M, Agne, Julia L, Presley, Carolyn J

“…Palliative care is beneficial for patients with advanced lung cancer, but the optimal model of palliative care delivery is unknown. We investigated healthcare…”
Get full text

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer by Li, Mingjia, Spakowicz, Daniel, Zhao, Songzhu, Patel, Sandip H., Johns, Andrew, Grogan, Madison, Miah, Abdul, Husain, Marium, He, Kai, Bertino, Erin M., Shields, Peter G., Wei, Lai, Carbone, David P., Otterson, Gregory A., Presley, Carolyn J., Owen, Dwight H.

“…Background Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that may complicate treatment with immune checkpoint inhibitors (ICI) and…”
Get full text

Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer by Owen, Dwight H., Williams, Terence M., Bertino, Erin M., Mo, Xiaokui, Webb, Amy, Schweitzer, Catherine, Liu, Tom, Roychowdhury, Sameek, Timmers, Cynthia D., Otterson, Gregory A.

“…•Chemotherapy remains an important treatment in non-small cell lung cancer.•Patients with homologous recombination mutations had worse survival.•Patients with…”
Get full text

Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA by Stinchcombe, Thomas E., Wang, Xiaofei, Doebele, Robert C., Drusbosky, Leylah M., Gerber, David E., Horn, Leora, Bertino, Erin M., Liu, Geoff, Villaruz, Liza C., Ross Camidge, D.

“…•Brigatinib demonstrated activity after second-generation ALK TKI’s.•The ORR was similar after 1st or 2nd line therapy with second generation ALK TKI’s.•ctDNA…”
Get full text